Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.0
4.5
Journals
Cancers
Special Issues
Building on the Success of Checkpoint Inhibitors to Overcome Resistance
share announcement

Building on the Success of Checkpoint Inhibitors to Overcome Resistance

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Drug Development".

Deadline for manuscript submissions: 10 May 2025 | Viewed by 491

Special Issue Editors

Dr. Tatiana I. Novobrantseva

E-Mail Website
Guest Editor
Verseau Therapeutics, Auburndale, FL, USA
Interests: immunology; oncology; immuno-oncology; immunotherapy; drug development
Dr. Igor Feldman

E-Mail Website
Guest Editor
Verseau Therapeutics, Auburndale, FL, USA
Interests: oncology; immuno-oncology; immunotherapy; drug development
Dr. Abdel Kareem Azab

E-Mail Website
Guest Editor
Department of Biomedical Engineering, UT Southwestern Medical Center, Dallas, TX, USA
Interests: drug resistance; immunotherapy; 3D tissue cultures; nanoparticles; cancer biology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

We are thrilled to announce a Special Issue titled "Building on the Success of Checkpoint Inhibitors to Overcome Resistance". This Special Issue focuses on exploring novel strategies and methods to overcome resistance to T cell checkpoint inhibitors. T cell checkpoint inhibitors have shown remarkable success in cancer treatment, but many patients are not responding and resistance can develop in those responding, limiting their efficacy. Consequently, researchers are actively seeking innovative approaches to address this resistance and increase the reach of immunotherapies. This Special Issue presents a collection of articles that highlight various innovative methods and strategies, including the following:

  • Clinical trials evaluating combination therapies and different dosing strategies: Highlighting ongoing clinical trials investigating the combination of immune checkpoint inhibitors with other treatment modalities, aiming to overcome resistance and improve patient outcomes. These trials explore the synergistic potential of combining immunotherapy with targeted therapy, immunotherapy, chemotherapy, or radiation therapy.
  • Novel checkpoint inhibitors: The development of new immune checkpoint inhibitors targeting different T cell checkpoints or targeting non-T cells to broaden the therapeutic scope and improve patient responses.
  • Overcoming tumor microenvironment-mediated resistance: Strategies that focus on modulating the tumor microenvironment to overcome T cell checkpoint inhibitor resistance, such as targeting immunosuppressive cells or factors within the tumor microenvironment.
  • By highlighting these innovative approaches, this Special Issue aims to provide valuable insights and advancements in the field of T cell checkpoint inhibitor resistance, ultimately contributing to the development of more effective and personalized cancer immunotherapies.

Dr. Tatiana I. Novobrantseva
Dr. Igor Feldman
Dr. Abdel Kareem Azab
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • immune checkpoint inhibitor
  • tumor microenvironment
  • immunotherapies
  • clinical evaluation
  • cancer treatment
  • drug resistance

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

27 pages, 3697 KiB  
Article
Preclinical Efficacy of VTX-0811: A Humanized First-in-Class PSGL-1 mAb Targeting TAMs to Suppress Tumor Growth
by Tatiana Novobrantseva, Denise Manfra, Jessica Ritter, Maja Razlog, Brian O’Nuallain, Mohammad Zafari, Dominika Nowakowska, Sara Basinski, Ryan T. Phennicie, Phuong A. Nguyen, Michael A. Brehm, Stephen Sazinsky and Igor Feldman
Cancers 2024, 16(16), 2778; https://doi.org/10.3390/cancers16162778 (registering DOI) - 6 Aug 2024
Abstract
Omnipresent suppressive myeloid populations in the tumor microenvironment limit the efficacy of T-cell-directed immunotherapies, become more inhibitory after administration of T-cell checkpoint inhibitors, and are overall associated with worse survival of cancer patients. In early clinical trials, positive outcomes have been demonstrated for [...] Read more.
Omnipresent suppressive myeloid populations in the tumor microenvironment limit the efficacy of T-cell-directed immunotherapies, become more inhibitory after administration of T-cell checkpoint inhibitors, and are overall associated with worse survival of cancer patients. In early clinical trials, positive outcomes have been demonstrated for therapies aimed at repolarizing suppressive myeloid populations in the tumor microenvironment. We have previously described the key role of P-selectin glycoprotein ligand-1 (PSGL-1) in maintaining an inhibitory state of tumor-associated macrophages (TAMs), most of which express high levels of PSGL-1. Here we describe a novel, first-in-class humanized high-affinity monoclonal antibody VTX-0811 that repolarizes human macrophages from an M2-suppressive phenotype towards an M1 inflammatory phenotype, similar to siRNA-mediated knockdown of PSGL-1. VTX-0811 binds to PSGL-1 of human and cynomolgus macaque origins without inhibiting PSGL-1 interaction with P- and L-Selectins or VISTA. In multi-cellular assays and in patient-derived human tumor cultures, VTX-0811 leads to the induction of pro-inflammatory mediators. RNAseq data from VTX-0811 treated ex vivo tumor cultures and M2c macrophages show similar pathways being modulated, indicating that the mechanism of action translates from isolated macrophages to tumors. A chimeric version of VTX-0811, consisting of the parental murine antibody in a human IgG4 backbone, inhibits tumor growth in a humanized mouse model of cancer. VTX-0811 is exceptionally well tolerated in NHP toxicology assessment and is heading into clinical evaluation after successful IND clearance. Full article
(This article belongs to the Special Issue Building on the Success of Checkpoint Inhibitors to Overcome Resistance)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop